Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GATTAquant is a private German life science tools company that develops and sells DNA origami-based nanorulers, fluorescent beads, cell slides, and analysis software for calibration, validation, and quantification of super-resolution and fluorescence microscopy systems. The company was founded in 2014 as a spin-off of the Technical University of Braunschweig and focuses on standards for imaging modalities such as STED, dSTORM, SIM, DNA-PAINT, confocal, AFM, and related workflows. Its products are used by microscopy researchers and instrument users to measure resolution, optimize instrument performance, and support reproducible imaging experiments. GATTAquant is not a therapeutic drug developer; it is a commercial provider of research-use nanotechnology products and imaging reference materials for the life sciences market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GATTAquant.